Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Tyra Biosciences Inc (TYRA)

Tyra Biosciences Inc (TYRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer PR Newswire - Mon Dec 1, 7:00AM CST

CARLSBAD, Calif. , Dec. 1, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...

TYRA : 22.63 (-0.79%)
Medical Laboratory by Gorodenkoff via Shutterstock
3 Biotech Stocks Wall Street Analysts Predict Will More Than Double Barchart - Thu Nov 20, 12:50PM CST

What makes analysts so bullish about these three names from the sector?

MEHCQ : 3.5000 (-2.78%)
GHRS : 13.03 (-5.54%)
TYRA : 22.63 (-0.79%)
DMAC : 9.39 (+0.54%)
XBI : 123.13 (+0.09%)
Tyra Biosciences Announces Participation at Upcoming Investor Events PR Newswire - Wed Nov 12, 3:05PM CST

CARLSBAD, Calif. , Nov. 12, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...

TYRA : 22.63 (-0.79%)
Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights PR Newswire - Wed Nov 5, 3:05PM CST

- Dosed first patients with dabogratinib in BEACH301 and SURF302; interim results from both studies expected in 2026 -

TYRA : 22.63 (-0.79%)
Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia PR Newswire - Thu Aug 21, 7:00AM CDT

-Dabogratinib is the only oral FGFR3-selective inhibitor in clinical development for achondroplasia-

TYRA : 22.63 (-0.79%)
Tyra Biosciences Announces Participation at Upcoming Investor Events PR Newswire - Wed Aug 20, 3:05PM CDT

CARLSBAD, Calif. , Aug. 20, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines...

TYRA : 22.63 (-0.79%)
Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights PR Newswire - Thu Aug 14, 3:05PM CDT

- Dosed first patient in SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC) -

TYRA : 22.63 (-0.79%)
Tyra Biosciences Announces Fireside Chat on Achondroplasia and Growth Disorders at UBS Biotech Management Live Call Series PR Newswire - Mon Jul 21, 3:05PM CDT

CARLSBAD, Calif. , July 21, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines...

TYRA : 22.63 (-0.79%)
Investors Eye Biotech Stocks as Cancer Therapies Take Center Stage in 2025 BayStreet.ca - Wed Jan 15, 8:06AM CST

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As the new year begins, the American Association for Cancer Research (AACR) has highlighted expert predictions...

ONCY : 0.9931 (-0.53%)
TYRA : 22.63 (-0.79%)
ZNTL : 1.4000 (-3.45%)
ONC.TO : 1.42 (+2.16%)
CMPX : 5.16 (-4.27%)
CCCC : 2.47 (-2.76%)
Tyra Biosciences Announces Oral Presentations on TYRA-300 for Achondroplasia at the ASBMR and ASHG 2023 Annual Meetings PR Newswire - Thu Sep 21, 2023

/PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that...

TYRA : 22.63 (-0.79%)

Barchart Exclusives

Inflation Data, AI Earnings and Other Can't Miss Items this Week Barchart - Sun Dec 14, 12:00PM CST
Markets enter a critical week still reeling from Friday's sharp selloff in technology and AI stocks following disappointing reactions to Oracle and Broadcom earnings that raised questions about AI infrastructure spending sustainability and return on massive capital investments. Here are 5 things to watch this week in the Market. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot